Can the patient take telmisartan and rosuvastatin at the same time?
Yes, telmisartan and rosuvastatin can be taken together safely—this combination is commonly used and well-tolerated, with no clinically significant drug interactions that would preclude concurrent use.
Evidence Supporting Concurrent Use
The FDA drug label for telmisartan does not list rosuvastatin as a contraindicated medication or one requiring dose adjustment 1. While the label discusses important warnings about hyperkalemia, renal function, and dual RAS blockade, there are no specific warnings against statin coadministration.
The 2016 American Heart Association guidelines on statin drug-drug interactions do not identify telmisartan (or any angiotensin receptor blocker) as having clinically significant interactions with rosuvastatin 2. The guidelines extensively detail interactions between statins and cardiovascular medications including calcium channel blockers, antiarrhythmics, and anticoagulants, but ARBs are notably absent from concern.
Pharmacokinetic Interaction Data
Multiple recent pharmacokinetic studies have directly evaluated this combination:
Coadministration increases rosuvastatin exposure modestly: Studies show telmisartan increases rosuvastatin Cmax by approximately 71-113% and AUC by 26-27% 3, 4, 5. This occurs because telmisartan inhibits ABCG2-mediated efflux transport of rosuvastatin 4.
Telmisartan exposure increases slightly: Rosuvastatin causes a mild 16-26% increase in telmisartan AUC 3, 6, 5.
Clinical significance is minimal: Despite these pharmacokinetic changes, investigators consistently concluded the interactions were "not considered clinically significant without safety concerns" 3 and that "the degree of drug interaction observed was not regarded as clinically significant" 5.
Clinical Efficacy and Safety Evidence
Real-world clinical trials demonstrate this combination is both effective and safe:
A 2024 randomized trial of telmisartan/amlodipine/rosuvastatin triple therapy showed excellent efficacy in reducing both blood pressure and LDL-C with no severe adverse events 7.
A 2025 meta-analysis confirmed that telmisartan-based combinations (including with rosuvastatin) have comparable safety profiles with no significant difference in treatment-emergent adverse events 8.
Fixed-dose combination formulations containing both drugs have been developed and proven bioequivalent to separate tablets, indicating regulatory acceptance of this combination 9, 10, 11.
Practical Considerations
No dose adjustments are required when initiating this combination. The pharmacokinetic changes fall within the therapeutic ranges of both medications and do not necessitate dosing modifications.
Monitor as you would for either drug alone:
- Blood pressure response to telmisartan
- Lipid panel response to rosuvastatin
- Renal function and potassium (standard for ARBs) 1
- Muscle symptoms (standard for statins)
Common pitfall to avoid: Do not confuse this safe combination with the problematic dual RAS blockade (combining telmisartan with ACE inhibitors or aliskiren), which IS contraindicated due to increased risks of hypotension, hyperkalemia, and renal dysfunction 1.
The combination of telmisartan and rosuvastatin is widely prescribed for patients with concurrent hypertension and dyslipidemia, supported by extensive pharmacokinetic data, clinical trials, and the availability of approved fixed-dose combination products.